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Abstract
A biosimilar is a biologic drug that is “highly similar to a reference (originator) product, with no clinically meaningful dif-
ferences between the two products in safety, purity, and potency”. Regulatory approval of a biosimilar is based on analyti-
cal, structural, and functional comparisons with the reference product, comparative nonclinical (in vivo) studies, clinical 
pharmacokinetics and/or pharmacodynamics, and immunogenicity. In addition, comparative clinical efficacy and safety 
assessments are usually conducted and, taken together, comprise the “totality of the evidence” supporting biosimilarity. 
For a biosimilar to meet the additional designation of interchangeability in the United States (US), the applicant must dem-
onstrate that the biological drug can be expected to produce the “same clinical result as the reference product in any given 
patient” and “if the biological drug is administered more than once to an individual, the risk in terms of safety or diminished 
efficacy of alternating or switching between the use of the biological drug and the reference product is no greater than the 
risk of using the reference product without such alternation or switch”. The challenges faced in conducting clinical studies 
to support a designation of interchangeability, as defined in the final interchangeability guidance from the US Food and 
Drug Administration, are considered. Potential alternative approaches to generating adequate and sufficient clinical data to 
support a designation of interchangeability are also presented.
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Key Points 
In the United States, an approved biosimilar can be des-
ignated as “interchangeable.”
The United States Food and Drug Administration 
expects clinical data to support a demonstration of inter-
changeability.
Clinical studies that support interchangeability should 
be designed primarily to evaluate if clinical performance 
is altered by multiple switching between a reference 
product and its biosimilar and whether such switching 
will result in differences in pharmacokinetics or immu-
nogenicity profiles.
1 Introduction
A biosimilar is a biologic drug that is “highly similar 
to a reference (originator) product, and for which there 
are no clinically meaningful differences between the two 
products in safety, purity, and potency” [1]. The develop-
ment and approval of a biosimilar is based on extensive 
analytical, structural, and functional comparisons with 
the reference product, comparative nonclinical (in vivo) 
studies, clinical pharmacokinetics (PK) and/or phar-
macodynamics (PD), and immunogenicity, and usually 
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comparative clinical efficacy and safety assessments. 
Taken together, these data comprise the “totality of the 
evidence” supporting a conclusion of biosimilarity [2]. 
Provided that there is sufficient scientific justification, a 
biosimilar can be approved for use in all indications held 
by the reference product by a process of extrapolation, 
without the need to conduct comparative clinical studies 
for each indication [1].
According to the Biologics Price Competition and 
Innovation Act (BPCIA) in the United States (US), a bio-
similar can be designated as “interchangeable”, whereby 
it may be substituted for the reference product without the 
intervention of the healthcare provider who prescribed the 
reference product [3]. This enables pharmacy-mediated 
substitution, where state laws allow [2]. Indeed, in most 
states, the biosimilar may be substituted for the reference 
product if the biosimilar is designated as interchangeable 
[2, 4, 5].
To meet the additional designation of interchangeability 
in the US (as defined in the BPCIA), “an applicant must 
provide sufficient information to demonstrate biosimilarity 
and also to demonstrate that the biological product can be 
expected to produce the same clinical result as the refer-
ence product in any given patient” [2]. Moreover, “if the 
biological product is administered more than once to an 
individual, the risk in terms of safety or diminished effi-
cacy of alternating or switching between the use of the 
biological product and the reference product is not greater 
than the risk of using the reference product without such 
alternation or switch” [2]. A biosimilar product that has 
satisfied the regulatory requirements for demonstrating 
biosimilarity can be expected to have the same benefits 
and risks as its reference product, regardless of whether 
it has obtained a designation of interchangeability [6, 7].
In contrast to the regulatory situation in the US, the 
European Medicines Agency (EMA) does not have the 
legal remit to designate a product as being interchangeable 
and has not authorized the designation of any product for 
automatic substitution by a pharmacist without the inter-
vention of the prescriber [8]. Instead, without requiring 
additional clinical studies, individual national regulatory 
authorities in the European Union (EU) may endorse the 
switching from one reference or biosimilar product to 
another at the pharmacy level without consent of the pre-
scriber (“automatic substitution”) [9].
The aim of this review is to consider the challenges in 
conducting clinical studies to support a designation of inter-
changeability, as defined in the guidance from the US Food 
and Drug Administration (FDA) [2]. In addition, potential 
alternative approaches to generating sufficient clinical evi-
dence to support a designation of interchangeability are 
presented.
2  Clinical Interchangeability Studies: 
Guidance from the FDA
Final guidance from the FDA provides an overview of the 
key scientific considerations in demonstrating interchange-
ability of a biosimilar with a reference product [2, 10]. The 
guidance also provides clarification regarding the clinical 
data that are expected to support demonstration of inter-
changeability, considerations for the design and analysis of 
clinical interchangeability studies, and recommendations 
regarding the use of a US-licensed reference product [2]. 
Furthermore, as described in the guidance, evidence to sup-
port the demonstration of interchangeability may be col-
lected as part of the marketing application package for initial 
biosimilar approval [2]. Once interchangeability between a 
reference product and its biosimilar has been demonstrated 
in patients with a disease for which the reference product 
is approved, the biosimilar may be designated as an inter-
changeable biosimilar for use in that and other diseases for 
which the reference product is licensed but in which the 
biosimilar was not studied [2].
2.1  Goal of Studies Expected to Support 
the Interchangeability Designation
The aim of clinical interchangeability studies is not to re-
establish similarity between a biosimilar and its reference 
product, but to meet the FDA’s expectations for the demon-
stration of interchangeability [2]. By definition, the biosimi-
lar has already been deemed by the FDA not to be clinically 
different from the reference product [1]. As such, there is lit-
tle reason to expect altered PK, heightened immunogenicity 
response, increased safety risk, or improved or diminished 
efficacy in patients who switch back and forth from a refer-
ence product to the corresponding biosimilar [2].
The FDA guidance on interchangeability mentions that 
one important possible concern of multiple switches back 
and forth between a reference product and its biosimilar 
is the potential for changes in immunogenicity [2]. There-
fore, “switching studies are designed to assess whether 
one product will affect the immune response to the other, 
once the switch occurs, and whether this will result in 
differences in immunogenicity or PK profiles” [2]. This 
perceived drawback of multiple switching between a ref-
erence product and its biosimilar is based on theoreti-
cal concerns and experience with switches between one 
biologic product and another that is different, and not 
its biosimilar [9, 11]. There is a low likelihood that the 
incidence, titers, or specificity of antidrug antibodies 
(ADAs) will increase or change as a result of multiple 
switches between a reference product and its biosimi-
lar. This is particularly the case if the ADA response is 
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highly restricted to the idiotype (anti-idiotypic antibod-
ies); as with infliximab and adalimumab [12]. In addition, 
for a biosimilar that has been approved by the FDA or 
EMA, other product characteristics that could increase 
the immunogenicity potential of the molecule itself, 
such as aggregates, impurities, and oxidation, will have 
been shown to be highly similar to those of the reference 
product.
If a heightened or altered immunogenicity response 
was to occur as a consequence of multiple switching 
between a reference product and its biosimilar, it could 
create the potential for neutralization of biosimilars, 
their reference products, and related endogenous pro-
teins; affect the PK and ultimately the efficacy of the 
product; and also result in hypersensitivity and other 
immune-mediated adverse events (AEs) [2]. In the sci-
entific community, controversy remains regarding the 
need to conduct extensive clinical studies to evaluate the 
effects of switching (including multiple switches) on PK 
or immunogenicity.
2.2  Design of Studies Expected by the FDA 
to Support the Interchangeability Designation
In its guidance, the FDA recommends two potential designs 
for switching studies to evaluate interchangeability [2]. The 
first approach—a “dedicated switching study”—starts with a 
“lead-in period of treatment with the reference product, fol-
lowed by a randomized two-arm period, with one arm incor-
porating switching between the proposed interchangeable 
product and the reference product (switching arm) and the 
other remaining as a non-switching arm receiving only the 
reference product (non-switching arm). The switching arm 
is expected to include at least two separate exposure peri-
ods to each of the two products (i.e., at least three switches, 
with each switch crossing over to the alternate product)” 
(Fig. 1) [2].
The second approach—the integrated study—is designed 
so that biosimilarity and interchangeability can be supported 
by a single investigation. In the integrated, two-part study 
design, biosimilarity of the proposed interchangeable prod-
uct and its reference product is assessed in the first stage 
with a parallel, head-to-head, comparative design. Subjects 
in the reference product arm are then re-randomized and, 
in the second stage, the dedicated switching study design 
is followed to evaluate interchangeability between the two 
products (Fig. 2) [3].
The FDA guidance provides recommendations to con-
duct clinical interchangeability studies in patients rather 
than in healthy volunteers, and to use PK parameters, rather 
than efficacy or safety endpoints, as primary endpoints. The 
guidance states that “the primary endpoint in a switching 
study or studies should assess the impact of switching or 
alternating between the use of the proposed interchangeable 
product and the reference product on clinical PK and PD 
(if available), since these assessments are generally most 
likely to be sensitive to changes in immunogenicity and/or 
exposure that may arise as a result of alternating or switch-
ing” [2, 3].
In addition, the FDA guidance provides recommendations 
on the evaluation of PK endpoints. The guidance states that 
“the last switching interval should be from the reference 
Assessment of PK equivalence
Co-primary endpoints:












#3 Does multiple switching lead to:
• Lower PK related to higher 
immunogenicity?
• Less efficacy, worse safety?  
Fig. 1  Design of a clinical switching study: dedicated approach [2]. 
Adapted from US Food and Drug Administration [2]. AUC t area 
under the concentration versus time curve in the dosing period, BS 
proposed interchangeable biosimilar product, Cmax maximum concen-
tration, PK pharmacokinetics, RP reference product
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product to the proposed interchangeable product, where 
the duration of exposure to the proposed interchangeable 
product after the last switch is sufficiently long to allow 
for washout of the reference product (i.e., at least three or 
more half-lives)”. This allows assessment of the PK of the 
proposed interchangeable product in the switching arm and 
comparison with the PK of the reference product in the non-
switching arm [2].
2.3  Primary Endpoints of Clinical Interchangeability 
Studies: Statistical PK Assessment
As outlined in the final FDA guidance, studies that sup-
port interchangeability are designed primarily to assess 
whether the clinical performance is altered by multiple 
switching between a reference product and its biosimilar 
and, more specifically, whether such switching will result 
in differences in PK or immunogenicity profiles [2]. The 
FDA guidance recommends that, for intravenous adminis-
tration, the area under the concentration versus time curve 
in the dosing period (AUC τ) should be considered as the 
primary study endpoint. For subcutaneous administration, 
the maximum (or peak) concentration (Cmax) and AUC 
τ should be considered as co-primary study endpoints 
[2]. These PK parameters should be analyzed using an 
equivalence approach, with the two-sided 90% confidence 
interval (CI) for the geometric mean ratio (GMR) of AUC 
τ and Cmax between the proposed interchangeable prod-
uct and the reference product being within the range of 
0.8–1.25 [2].
2.4  Current Evidence on the Effects of Switching
Most switching data pertaining to biosimilars are from stud-
ies designed to evaluate the effects of a single switch from 
a reference product to its biosimilar. A review of published 
data from clinical trials and post-marketing surveillance 
found no evidence to suggest that switching between bio-
similars and their corresponding reference products results 
in significant safety concerns [13, 14]. Indeed, in the EU, the 
demonstration of biosimilarity, with rigorous post-marketing 
pharmacovigilance, is considered to be adequate to support 
switching in clinical practice [9, 14].
A systematic literature review of switching studies 
between related biologics (including biosimilars) identi-
fied no increased risk of immunogenicity-related AEs or 
decreased efficacy after a single switch from, or multiple 
switches between, a reference product and its biosimilar 
[15]. Recent studies have also shown that multiple switching 
between a reference product and its biosimilar has no appar-
ent effect on efficacy, safety, or immunogenicity [16–18]. 
These multiple-switch studies were not designed to meet 
the FDA’s designation of interchangeability because they 
did not assess PK parameters as primary endpoints, which is 
expected by the FDA [2]. However, many have demonstrated 
comparable efficacy, safety, and immunogenicity of the bio-
similar to its reference product among patients who switched 
from the reference product to the biosimilar, compared to 
those who continued treatment with the biosimilar.
For example, in open-label extensions of the PLANE-















Fig. 2  Design of a clinical switching study: integrated approach [2, 
3]. “Sowing confusion in the field: the interchangeable use of biosim-
ilar terminology,” Laura McKinley (US Regulatory Policy), John M. 
Kelton (US Medical Affairs), and Robert Popovian (US Government 
Relations), Current Medical Research and Opinion, 2019, Published 
by Taylor & Francis. Adapted by permission of the publisher Informa 
UK Limited trading as Taylor & Francis Ltd, https ://www.tandf onlin 
e.com [3]. BS proposed interchangeable biosimilar product, RP refer-
ence product
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infliximab-dyyb to reference infliximab in patients with 
RA and ankylosing spondylitis, respectively, patients who 
switched from reference infliximab to infliximab-dyyb had 
efficacy, safety, and immunogenicity outcomes similar to 
those of patients who continued treatment with infliximab-
dyyb [19, 20]. In addition, the NOR-SWITCH study, a ran-
domized, double-blind non-inferiority trial that assessed 
switching from reference infliximab to biosimilar infliximab-
dyyb in patients with any of six different immune-mediated 
inflammatory diseases, demonstrated that switching from 
reference infliximab to infliximab-dyyb (switch group) was 
not inferior to continuing treatment with reference infliximab 
(maintenance group). Overall, disease worsening occurred 
in 26% and 30% of patients in the maintenance and switch 
groups, respectively. The safety profile was also similar 
between the maintenance and switch groups [21]. Similar 
outcomes were observed among patients who switched from 
reference infliximab to infliximab-dyyb during the 26-week, 
open-label extension [22].
Three switches between biosimilar etanercept GP2015 
 (Erelzi®; etanercept-szzs; Sandoz International GmbH, 
Holzkirchen, Germany; Sandoz, Inc., West Princeton, NJ, 
USA) and etanercept reference product  (Enbrel®, Amgen 
Inc., Thousand Oaks, CA, USA; EU authorized) did not 
adversely affect efficacy, safety, or immunogenicity in 
patients with chronic plaque-type psoriasis [16]. Switching 
five times between biosimilar filgrastim EP2006  (Zarxio®; 
filgrastim-sndz; Sandoz International GmbH, Holzkirchen, 
Germany; Sandoz, Inc., West Princeton, NJ, USA) and fil-
grastim reference product  (Neupogen®, Amgen Inc., Thou-
sand Oaks, CA, USA) did not result in clinically meaningful 
differences in efficacy or safety in patients with breast cancer 
[17]. Switching four times between biosimilar adalimumab 
GP2017  (Hyrimoz®; adalimumab-adaz; Sandoz Interna-
tional GmbH, Holzkirchen, Germany; Sandoz, Inc., West 
Princeton, NJ, USA) and adalimumab reference product 
 (Humira®, AbbVie Ltd, Maidenhead, UK; AbbVie Inc., 
North Chicago, IL, USA) resulted in no detectable impact on 
efficacy, safety, or immunogenicity in patients with active, 
clinically stable, moderate-to-severe plaque psoriasis [18].
Assessing the effects of switching in a “real-world” set-
ting can be challenging, as patients may be switched back 
and forth among different products in clinical practice [23]. 
Observational studies of the use of epoetins and granulocyte 
colony-stimulating factors in patients with chronic kidney 
disease or cancer in Italy have demonstrated that there is 
frequent switching between different biological products 
belonging to the same class in routine clinical care [24, 25]. 
Post-marketing studies conducted in population-based data-
bases have provided additional evidence of the comparative 
effectiveness and safety of originator and biosimilar epoet-
ins, and have shown that switching from originator epoetin 
to a biosimilar epoetin, or vice versa, is safe and effective 
[26–28].
Moreover, experience from the DANBIO registry 
revealed no negative impact of switching from infliximab 
reference product  (Remicade®, Janssen Biologics B.V., Lei-
den, The Netherlands; Janssen Biotech, Inc., Horsham, PA, 
USA) to biosimilar infliximab CT-P13  (Inflectra®; inflix-
imab-dyyb; Pfizer Inc., New York, NY, USA;  Remsima®, 
Celltrion Healthcare, Co., Ltd, Incheon, Korea) on disease 
activity in patients with rheumatoid arthritis (RA), psoriatic 
arthritis (PsA), or axial spondyloarthritis [29]. The adjusted 
1-year retention rate was lower in the infliximab-dyyb group 
compared with that among patients who received infliximab 
reference product. However, this study had several limita-
tions, including incomplete data due to the observational 
approach, and the potential nocebo effect in patients in 
the infliximab-dyyb group. The nocebo effect refers to the 
emergence of new or worsening symptoms brought about by 
negative expectations regarding a therapeutic intervention, 
either inert or active [30–32]. In the BIO-SWITCH study, 
small changes in disease activity indices observed in patients 
with RA, PsA, and axial spondyloarthritis were also attrib-
uted to the nocebo effect [33].
3  Challenges with the Use of PK Endpoints 
in Supporting Interchangeability
The FDA guidance states that interchangeability is sup-
ported if the 90% CI of the ratio of the log-normally distrib-
uted PK parameters for systemic drug exposure, Cmax and 
AUC τ, between the proposed interchangeable product and 
the reference product falls completely within the symmetric 
bioequivalence range of 80–125% (symmetric on the log 
scale) [34]. This arbitrarily determined range is the same as 
that used in PK bioequivalence studies comparing proposed 
generic small-molecule drugs to their reference products, 
based upon the assumption that a difference in systemic drug 
exposure of up to 20% is not clinically significant. These 
margins have also been used to establish PK similarity in 
clinical studies comparing biosimilars to their reference 
products [2]. However, it is important to recognize that, in 
an interchangeability study, these PK assessments are not 
intended to re-establish PK similarity between the biosimilar 
and its reference product, but rather serve as sensitive out-
come measures to assess the impact of multiple switching 
between a reference product and its biosimilar on therapeutic 
drug concentrations [2].
It is important to note that the establishment of symmetric 
equivalence margins of 80–125% for Cmax and AUC τ does 
not consider biologic plausibility (e.g., the known effect of 
potential immunogenicity on the PK of a given molecule). 
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For certain molecules (e.g., monoclonal antibodies such as 
adalimumab and infliximab), the occurrence of ADAs affects 
PK only in one direction (i.e., lowering plasma drug levels). 
Therefore, investigating the possibility of increased drug lev-
els after multiple switches for these molecules might not be 
warranted, since such an occurrence is unlikely. The clinical 
relevance of differences in PK on efficacy and safety, both of 
which are potential concerns with interchangeability, should 
also be considered. Indeed, for certain products, a differ-
ence of 25% in Cmax and AUC τ might not have a discernible 
effect on safety or efficacy (e.g., drugs with clinical doses 
that yield concentrations at the plateau of the therapeutic 
concentration–effect curve).
Several challenges are associated with the use of PK end-
points in clinical interchangeability studies. The sample size 
required for PK studies conducted in patients, rather than 
in healthy volunteers, may be relatively large for certain 
products (e.g., subcutaneously administered drugs) because 
of a high coefficient of variation (CV) for PK parameters. 
For example, it has been reported that the estimated CV 
for adalimumab is ~ 50% for Cmax or AUC τ in patients, 
compared with that of ~ 30% in healthy volunteers [35]. 
Additionally, determination of AUC τ and Cmax in patients 
requires intense sampling with multiple PK assessments 
over a relatively short period of time. Dosing and sampling 
deviations may occur, which could contribute to increased 
variability. Moreover, the high variability of PK parameters 
observed in patients may be due to several factors, such as 
the use of concomitant medications and the wide distribu-
tion of body weights, serum albumin levels, and disease 
activity.
In addition, the need for intensive PK sampling to assess 
Cmax and AUC τ requires multiple blood draws, which adds 
to patient burden and could negatively affect study enroll-
ment and, importantly, increase dropout and rates of non-
evaluable subjects (e.g., number of subjects who would not 
be evaluable for PK assessments). The combination of high 
PK variability and the rate of non-evaluable PK could render 
dedicated clinical interchangeability studies, which follow 
the FDA guidance strictly, unnecessarily large.
Furthermore, since the occurrence of ADAs has been 
described to affect PK in one direction only, by lowering 
plasma drug levels, a two-sided CI using asymmetric mar-
gins (with “relaxation” of the upper margin) may be a more 
meaningful approach for studies supporting interchange-
ability. Table 1 shows the sample size requirements for 
an interchangeability study of a biosimilar with reference 
adalimumab conducted in patients with RA, comparing one 
with the symmetric equivalence margins of 80–125%, as 
recommended in the FDA guidance [2], to an example of one 
with asymmetric margins of 80–140%. Using asymmetric 
margins could allow for a smaller sample size in cases where 
the GMR is ≥ 100%.
4  Challenges with the Use 
of Immunogenicity Assessments 
in Supporting Interchangeability
The FDA guidance states that clinical interchangeability 
studies should assess immunogenicity and be analyzed 
descriptively as a secondary endpoint [2]. We agree that a 
descriptive analysis of immunogenicity is adequate, as there 
are currently no established margins corresponding to the 
clinical relevance of differences in immunogenicity. Moreo-
ver, it is not possible to make meaningful comparisons of 
compounds with a low incidence of ADAs.
We believe that a key focus in assessing interchangeabil-
ity should be examination of the evolution of immunogenic-
ity profiles of the biosimilar and corresponding reference 
product as a consequence of switching. However, as simi-
larity already has been established between the biosimilar 
and its reference product, it is expected that their immuno-
genicity profiles will be similar after alternating treatment 
between the biosimilar and reference product in patients. 
For example, studies of switching between biosimilar adali-
mumab ABP-501 (Amjevita™; adalimumab-atto; Amgen 
Inc., Thousand Oaks, CA, USA;  Amgevita®, Amgen Europe 
B.V., Breda, The Netherlands) and the adalimumab reference 
product  (Humira®) in patients with psoriasis showed that 
immunogenicity (as measured by antibody detection) was 
not affected by switching between treatments [36].
Table 1  Total sample size required for 90% co-primary  powera for 
symmetric and asymmetric equivalence margins
AUCτ area under the concentration versus time curve in the dosing 
period, CI confidence interval, Cmax maximum (or peak) concentra-
tion, CV coefficient of variation common to AUC τ and Cmax, GMR 
geometric mean ratio common to AUC τ and Cmax
a Co-primary power is the probability that the 90% CI for the GMR 
lies within the equivalence margins for both AUC τ and Cmax. For 
illustration purposes, AUC τ and Cmax are treated as uncorrelated; the 
required sample size will be slightly smaller if these parameters are 
positively correlated
b Attrition rate is the expected attrition from the analyses of AUC τ and 
Cmax
c Total sample size is the evaluable sample size required in the analy-
sis, assuming 1:1 randomization; total enrolled sample size: required 
enrolled sample size taking into account attrition from the analysis
GMR Equivalence 
margins (%)








95% 80–125 50 25 326 436
80–140 50 25 326 436
100% 80–125 50 25 234 312
80–140 50 25 194 260
105% 80–125 50 25 318 424
80–140 50 25 150 200
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Furthermore, according to FDA guidance, a comparative 
clinical immunogenicity study (e.g., switching study) may 
be unnecessary to support the demonstration of biosimilarity 
or interchangeability for insulin products [37]. In contrast to 
other biologics, such as monoclonal antibodies, insulin is a 
relatively small protein with a straightforward structure that 
is well-characterized. Thus, if a comprehensive analytical 
evaluation demonstrates that the proposed biosimilar insu-
lin is “highly similar” to its reference product, then “there 
would be little or no residual uncertainty regarding immu-
nogenicity” and “minimal or no risk of clinical impact from 
immunogenicity” would be expected [37].
Finally, although switching between a reference product 
and its biosimilar is not expected to trigger immunogenicity, 
it is important to note that changes in the delivery device 
or formulation of any biological medication may result 
in increased immunogenicity. For example, after changes 
were made to both the formulation and delivery device of 
an epoetin alfa reference product, patients with chronic kid-
ney disease who received this reference biologic medica-
tion developed anti-erythropoietin antibodies that resulted 
in fatal cases of pure red cell aplasia [11, 38–40]. However, 
the potential impact of such manufacturing changes on the 
safety and efficacy of a biologic product is evaluated accord-
ing to a separate regulatory process for conducting a com-
parability assessment, which is distinct from the regulatory 
assessment of biosimilarity [41].
5  Challenges with the Use of Efficacy 
and Safety Endpoints in Clinical 
Interchangeability Studies
The FDA guidance states that “although assessments of effi-
cacy endpoints can be supportive, at therapeutic doses many 
clinical efficacy outcomes would only be sensitive to large 
changes in exposure or immunogenicity, which may not be 
observed in a study of limited duration and with a limited 
number of switches” [2]. In addition, the use of efficacy and 
safety endpoints can present potential challenges in clinical 
interchangeability studies. It can be challenging to conduct a 
fully blinded study if different formulations of the biosimilar 
and its reference product are used, with potential differences 
in injection-site reactions or pain [42]. The nocebo effect 
may influence the assessment of efficacy, especially if the 
study is not fully blinded [43]. The FDA recognizes that 
efficacy endpoints are measured with less precision than PK 
parameters, perhaps necessitating larger sample sizes if an 
efficacy parameter is considered as the primary endpoint, 
and therefore should be analyzed descriptively [2].
The use of established efficacy endpoints in biosimilar 
trials may not be sensitive enough to detect potential dif-
ferences in efficacy between a biosimilar and its reference 
product, since the use of such endpoints has not differenti-
ated between two dissimilar biologic agents with distinct 
mechanisms of action. In the AMPLE trial, which compared 
subcutaneous administration of abatacept to that of adali-
mumab over 2 years in patients with RA, all clinical efficacy 
outcome measures [American College of Rheumatology 
(ACR) responses, changes in Disease Activity Score in 28 
joints using the C-reactive protein (DAS28-CRP) improve-
ment in the Health Assessment Questionnaire–Disability 
Index (HAQ-DI), and radiographic progression] yielded 
essentially the same results for both drugs over the 2-year 
study duration, despite abatacept and adalimumab having 
completely different mechanisms of action [44].
6  Are Multiple‑Switch Clinical Trials Needed 
to Support Interchangeability?
In light of the high standards for biosimilar approval in the 
US, biologic plausibility of the effect of switching, accumu-
lated clinical evidence, and limitations of the endpoints used 
in interchangeability studies, there has been discussion in the 
scientific community regarding the need to re-evaluate how 
interchangeability is determined [45].
We believe that the FDA should be flexible when con-
sidering statistical approaches, endpoints, and overall study 
design for interchangeability switching studies. For exam-
ple, the potential use of asymmetric margins, or even a non-
inferiority design, rather than symmetric margins could be 
considered as an alternative statistical approach to test the 
equivalence of PK endpoints when it is known that immu-
nogenicity could only hasten drug clearance. Efficacy end-
points, ideally including appropriate surrogate biomarkers, 
could be used instead of PK endpoints, particularly when the 
immunogenicity potential of the drugs is low.
Currently, as experience with multiple switches of 
biosimilars has been limited, there is a regulatory expec-
tation to perform multiple-switch trials to support an 
interchangeability designation. However, it may not be 
possible to fully blind such switching trials to minimize 
the nocebo effect. In addition, the design of such multi-
ple-switch trials has ethical implications. For example, 
the need for multiple in-patient visits and intensive PK 
sampling to assess PK parameters would add to patient 
burden. Understandably, the current regulatory expecta-
tions for demonstrating interchangeability are conserva-
tive. However, over time, the FDA may conclude that 
switching studies are unnecessary to support an inter-
changeability designation as new evidence (e.g., results 
from clinical trials and real-world observational studies) 
emerges to show that PK, immunogenicity, and efficacy 
are not affected by multiple switches between a reference 
product and its biosimilar.
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On a case-by-case and individual product basis, and 
when scientifically justified, the FDA should support 
alternative study designs that could hasten the develop-
ment process without affecting the ability to ensure that 
the risk in terms of alternating or switching between use 
of the interchangeable biological product and its reference 
product is not greater than the risk of using the reference 
product without switching. For example, the designation 
of interchangeability could be supported by the current 
analytical, functional, and clinical data that are required 
to establish biosimilarity, and complemented by post-mar-
keting surveillance in registries or pragmatic randomized 
controlled trials that focus on patient-centered outcomes, 
such as tolerability and adherence [9, 46].
7  Conclusions
From a clinical perspective, the risk associated with 
switching between a biologic reference product and its 
biosimilar is improbable. The potential for changes in 
immunogenicity, such as a heightened or altered immu-
nogenic response, as a consequence of switching between 
a reference product and its biosimilar is not supported 
by current evidence. However, there is a legal require-
ment to demonstrate that “for a biological product that 
is administered more than once to an individual, the risk 
in terms of safety or diminished efficacy of alternating or 
switching between use of the biological product and the 
reference product is not greater than the risk of using the 
reference product without such alternation or switch” [2]. 
The use of PK parameters as primary endpoints for clini-
cal interchangeability studies to support an interchange-
ability designation of biosimilars creates new challenges. 
Interchangeability should be assessed on a case-by-case 
basis, considering the “totality of the evidence” and bio-
logic plausibility. Alternative approaches to statistical 
analysis (e.g., use of asymmetric rather than symmetric 
margins to test equivalence) and study designs that meet 
the FDA’s expectations for demonstration of interchange-
ability should be considered.
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